Cancer
Mapping the Tumor Immune Microenvironment: Spatial Biology Insights into Immunotherapy Response in NSCLC
Lung cancer is a formidable foe. Globally, it is the leading cause of cancer-related deaths in men and women, with non-small lung cancer (NSCLC) representing more than 80% of all…
Synaptic Dysfunction and Neuroinflammation: Complementary Pathways Driving Cognitive Decline
Accelerator Laboratory Services: The Biomarker Powerhouse
Proteomics in Transition: From Discovery to Diagnostic Utility
The promise of proteomics lies in its ability to illuminate disease biology at scale, transform translational research, and guide the development of precision diagnostics and targeted therapies. While genomic technologies…
Built for Translation: Why Simoa Stands Alone in Clinical-Grade Biomarker Measurement
Translating proteomic discovery into clinical action requires more than scale, it demands precision, reproducibility, and quantitative clarity. The Quanterix Simoa® digital immunoassay technology was purpose-built to meet the demands of…
YKL-40 Emerges as a Key Indicator of Neuroinflammatory-Driven Tau Pathology and Brain Atrophy in Alzheimer’s Disease
Alzheimer’s disease (AD) is increasingly understood as a multifaceted disorder involving not only amyloid and tau pathology, but also significant contributions from neuroinflammation and vascular dysfunction. In particular, astrocyte reactivity…
Looking Ahead: Key Takeaways from AAIC 2025
The 2025 Alzheimer’s Association International Conference (AAIC) brought the global neuroscience community to share breakthrough science, policy priorities, and tools like never before. It was an incredible week of conversation, innovation and…
Neurology
AAIC 2025: A Showcase of Simoa-Powered Innovation and Integration in Alzheimer’s Research
Next week, researchers from around the globe will gather in Toronto for the Alzheimer’s Association International Conference (AAIC) 2025, and Quanterix is proud to be at the center of the…
Neurology
Blood-based Brain Injury Biomarkers: Revealing the Hidden Story of Brain Health
Every year, countless individuals experience head injuries, often with effects that linger long after the initial incident. Whether from a fall at home, a fender-bender on the road, or a…
Immunology
Unlocking Ultra-Sensitive Cytokine Detection: Insights from the Frontage & Quanterix Webinar
On June 11, 2025, Quanterix and Frontage Laboratories co-hosted a compelling webinar focused on improving cytokine biomarker quantification using the Simoa® platform. The session featured Jingwen Tan, Ph.D., Director of…
Neurology
Refining the Alzheimer’s Biomarker Framework: Integrating p-Tau 205 and p-Tau 212 for Comprehensive Disease Profiling
Advances in Alzheimer’s biomarker science have transformed early detection and stratification, laying the groundwork for more personalized approaches to care. Yet as the field shifts toward tracking disease dynamics with…
Neurology
NfL as a Biomarker in ALS: Insights from Investigational Research on Enoxacin
Introduction ALS is a fatal neurodegenerative disease that progressively impairs motor function, leading to paralysis. Current treatments focus on symptom management, with tofersen recently approved as the first disease-modifying therapy…